Skip to search formSkip to main contentSkip to account menu

emicizumab

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ACE910

Broader (2)

Antibodies, BispecificAntibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Emicizumab: nuevo tratamiento para personas con hemofilia A con y sin inhibidor
Hemophilia A is an hereditary hemorragic disorder due to FVIII deficiency. In severe disease (FVIII< 1%), bleeding should be… 
2019
2019
PF331 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE
2019
2019
Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.
Review
2019
Review
2019
Emicizumab for haemophilia A.
2018
2018
Emicizumab in persons with hemophilia A (PwHA) without inhibitors: Results from HAVEN 3 study
2018
2018
FDA Approves Emicizumab-kxwh for Hemophilia A
Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood… 
2017
2017
Positive phase III results for Roche ’ s emicizumab in haemophilia
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine ● HAVEN 1… 
2017
2017
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
2016
2016
Replacing factor VIII replacement
Medicine Hemophilia A is a bleeding disorder caused by a deficiency of factor VIII, a protein essential for blood clotting… 
2016
2016
Emicizumab. Anti-factor IXa and X monoclonal antibody, Treatment of congenital FVIII deficiency (hemophilia A)